Telomir selects Linical for Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer
TELO•Telomir Pharmaceuticals selected Linical to support its FDA-cleared Phase 1/2 trial of Telomir-Zn in advanced or metastatic triple-negative breast cancer, with clinical initiation targeted for the first quarter of 2027.
1. Trial support selected
Telomir Pharmaceuticals selected Linical to support its Phase 1/2 trial of the oral therapy Telomir-Zn in advanced or metastatic triple-negative breast cancer. Clinical initiation is targeted for the first quarter of 2027, supported by executed clinical trial agreements.
2. Study objectives
The study will evaluate Telomir-Zn alone for safety, tolerability and preliminary antitumor activity. Preclinical research has demonstrated antitumor activity in triple-negative breast cancer models.




